Presentation Type
Oral Presentation
Keywords
Roche Pharmaceuticals, Central Nervous System, Alzheimer's Disease, Biopharmaceutical Industry
Department
Business Administration
Major
Business Administration
Abstract
Roche is the fifth largest pharmaceutical and biotechnology company in the world with $52B in sales during 2013 and 4.9% market share in the pharmaceutical industry. Its main competitors include Novartis, Pfizer, Johnson & Johnson, Sanofi, Merck & Co., and GlaxoSmithKline. Roche’s mission is to develop treatments for medical needs that have gone unmet and to create more efficient treatment options through cutting edge research. The Central Nervous System market segment makes up 19.6% of total industry sales and includes products treating such ailments as depression, epilepsy, psychosis, and Alzheimer’s disease. Though historically Roche has been a market leader in this segment, in recent years its Share of Market (SOM) has declined. Alzheimer’s disease is a progressive degenerative illness that causes memory loss, personality changes, loss of mobility, and death. Currently 35MM people, word wide, are suffering from the disease. The greatest predictors of Alzheimer’s disease are age and genetics. Therefore the number of people infected with the disease is expected to increase dramatically in the coming years as the global populate ages. Currently there are five FDA approved treatments for the disease, however they are ineffective as the best possible outcome is an increase in life expectancy of only 12 months. The objective of this undergraduate research project is to recommend a central nervous system corporate strategy for Roche, which would involve the development of a new drug to treat Alzheimer’s disease. This strategy would help Roche to retain or even strengthen its SOM against competitors.
Faculty Mentor
Dr. Venkatachalam Seshan
Funding Source or Research Program
Academic Year Undergraduate Research Initiative
Presentation Session
Session C
Location
Rockwell Academic Center 170
Start Date
3-4-2015 4:15 PM
End Date
3-4-2015 4:30 PM
Kali Jelen Roche Pharm AYURI Deck
Central Nervous System Strategy for Roche Pharmaceuticals
Rockwell Academic Center 170
Roche is the fifth largest pharmaceutical and biotechnology company in the world with $52B in sales during 2013 and 4.9% market share in the pharmaceutical industry. Its main competitors include Novartis, Pfizer, Johnson & Johnson, Sanofi, Merck & Co., and GlaxoSmithKline. Roche’s mission is to develop treatments for medical needs that have gone unmet and to create more efficient treatment options through cutting edge research. The Central Nervous System market segment makes up 19.6% of total industry sales and includes products treating such ailments as depression, epilepsy, psychosis, and Alzheimer’s disease. Though historically Roche has been a market leader in this segment, in recent years its Share of Market (SOM) has declined. Alzheimer’s disease is a progressive degenerative illness that causes memory loss, personality changes, loss of mobility, and death. Currently 35MM people, word wide, are suffering from the disease. The greatest predictors of Alzheimer’s disease are age and genetics. Therefore the number of people infected with the disease is expected to increase dramatically in the coming years as the global populate ages. Currently there are five FDA approved treatments for the disease, however they are ineffective as the best possible outcome is an increase in life expectancy of only 12 months. The objective of this undergraduate research project is to recommend a central nervous system corporate strategy for Roche, which would involve the development of a new drug to treat Alzheimer’s disease. This strategy would help Roche to retain or even strengthen its SOM against competitors.